| Company Name: |
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
|
| Tel: |
025-66099280 17798518460 |
| Email: |
cfzhang@aikonchem.com |
| Products Intro: |
Product Name:Verubecestat Trifluoroacetate
CAS:2095432-65-6
Purity:95% Package:1g;5g;10g
|
Verubecestat Trifluoroacetate manufacturers
- Verubecestat TFA
-
- $1980.00 / 50mg
-
2024-10-24
- CAS:2095432-65-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Verubecestat Trifluoroacetate Basic information |
| Product Name: | Verubecestat Trifluoroacetate | | Synonyms: | (R)-5-Fluoro-N-(4-fluoro-3-(3-imino-2,5-dimethyl-1,1-dioxido-1,2,4-thiadiazinan-5-yl)phenyl)picolinamide 2,2,2-trifluoroacetate;Verubecestat (TFA);Verubecestat Trifluoroacetate | | CAS: | 2095432-65-6 | | MF: | C19H18F5N5O5S | | MW: | 523.44 | | EINECS: | | | Product Categories: | | | Mol File: | 2095432-65-6.mol |  |
| | Verubecestat Trifluoroacetate Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO: 81 mg/mL (154.75 mM);Ethanol: 5 mg/mL (9.55 mM) | | Water Solubility | Water: Insoluble |
| | Verubecestat Trifluoroacetate Usage And Synthesis |
| Biological Activity | Verubecestat (MK-8931) Trifluoroacetat is a potent and selective beta-secretase inhibitor, a BACE1 inhibitor. | | in vitro | Verubecestat(MK-8931) effectively reduces Aβ40 in cells, Ki：7.8 nM and IC50 ：13 nM. | | in vivo | single oral dose of Verubecestat (MK-8931) to rats and cynomolgus monkeys significantly reduced cerebrospinal fluid (CSF) and cortical Aβ40. MK-8931 has an in vivo half-life of 20 hours, and is suitable for a once-daily dosing frequency. | | target | | Target | Value | BACE2
(Cell-free assay) | 0.37 nM(Ki) | BACE1
(Cell-free assay) | 1.75 nM(Ki) |
|
| | Verubecestat Trifluoroacetate Preparation Products And Raw materials |
|